Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ADXN

Addex Therapeutics Ltd ADR

Apr 23 • 04:00PM ET

18.74

Dollar change -0.54
Percentage change -2.80	%

Healthcare • Biotechnology • Switzerland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-18.70	Insider Own	0.03%	Shs Outstand	0.79M	Perf Week	-17.08%
Market Cap	14.80M	Forward P/E	3.60	EPS next Y	5.20	Insider Trans	0.00%	Shs Float	0.79M	Perf Month	59.90%
Income	-11.76M	PEG	-	EPS next Q	-	Inst Own	19.02%	Short Float	1.10%	Perf Quarter	165.82%
Sales	1.83M	P/S	8.09	EPS this Y	-178.90%	Inst Trans	-	Short Ratio	0.49	Perf Half Y	129.10%
Book/sh	1.71	P/B	10.94	EPS next Y	135.79%	ROA	-162.63%	Short Interest	0.01M	Perf Year	26.79%
Cash/sh	5.81	P/C	3.23	EPS next 5Y	-	ROE	-352.80%	52W Range	5.00 - 27.90	Perf YTD	209.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.98%	ROI	-814.63%	52W High	-32.83%	Beta	1.45
Dividend TTM	-	Quick Ratio	1.46	Sales past 5Y	-14.72%	Gross Margin	-	52W Low	274.80%	ATR (14)	2.52
Dividend Ex-Date	-	Current Ratio	1.46	EPS Y/Y TTM	69.94%	Oper. Margin	-627.35%	RSI (14)	51.42	Volatility	15.05% 12.83%
Employees	23	Debt/Eq	0.30	Sales Y/Y TTM	21.02%	Profit Margin	-644.20%	Recom	3.50	Target Price	21.05
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	46.71%	Payout	-	Rel Volume	0.73	Prev Close	19.28
Sales Surprise	-43.23%	EPS Surprise	-521.24%	Sales Q/Q	-66.65%	Earnings	Apr 18 BMO	Avg Volume	17.81K	Price	18.74
SMA20	-2.20%	SMA50	33.65%	SMA200	93.82%	Trades		Volume	12,934	Change	-2.80%

Apr-19-24 01:00AM	Addex to Present at the Swiss Biotech Day 2024 (GlobeNewswire)
Apr-18-24 06:52AM	ADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023 (InvestorPlace)
01:00AM	Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-11-24 01:00AM	Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 (GlobeNewswire)
Apr-03-24 01:00AM	Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders (GlobeNewswire) +16.35%
02:00AM	Loading…
Mar-14-24 02:00AM	Addex to Present at the Bio-Europe Spring 2024 Conference (GlobeNewswire)
Jan-31-24 01:00AM	Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. (GlobeNewswire)
Jan-09-24 01:00AM	Addex to Present at the Swiss Equities Baader Conference (GlobeNewswire)
Jan-05-24 01:30AM	Addex to Present at Biotech Showcase 2024 (GlobeNewswire) +6.69%
Dec-20-23 01:00AM	Addex Shareholders Approve All Resolutions at Extraordinary General Meeting (GlobeNewswire)
Dec-14-23 01:00AM	Addex Creates Treasury Shares (GlobeNewswire)
Nov-29-23 01:21AM	Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts (RTT News)
01:00AM	Addex Reports Q3 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-28-23 01:00AM	Addex Convenes Extraordinary General Meeting (GlobeNewswire)
Nov-23-23 01:00AM	Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023 (GlobeNewswire)
01:00AM	Loading…
Nov-14-23 01:00AM	Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients (GlobeNewswire) +10.91%
Nov-08-23 01:00AM	Addex Regains Nasdaq Listing Compliance (GlobeNewswire)
Nov-02-23 02:00AM	Addex Announces Participation in the Bio-Europe 2023 Conference (GlobeNewswire) -11.67%
Oct-20-23 01:00AM	Addex Completes ADS Ratio Change (GlobeNewswire) -19.49%
Oct-06-23 04:00PM	Addex Announces Plan to Implement ADS Ratio Change (GlobeNewswire) +12.77%
Oct-05-23 11:20AM	Addex Therapeutics focused on securing new partnerships to fund promising treatments (News Direct) +8.36%
Sep-20-23 01:00AM	Addex mGlu2 NAM Cognition Program Receives 4 Million Grant (GlobeNewswire)
Sep-06-23 01:00AM	Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.75%
Sep-05-23 01:00AM	Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 (GlobeNewswire) +16.81%
Sep-04-23 01:00AM	Addexs Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain (GlobeNewswire)
Aug-10-23 01:00AM	Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-23 01:00AM	Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023 (GlobeNewswire)
Aug-03-23 01:00AM	Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration (GlobeNewswire)
Jul-24-23 01:00AM	Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder (GlobeNewswire)
Jun-15-23 01:00AM	Addex Increases Issued Share Capital to Create Treasury Shares (GlobeNewswire)
01:00AM	Loading…
Jun-01-23 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire) +7.67%
May-18-23 01:00AM	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
May-11-23 01:00AM	Addex Reports Q1 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.70%
May-10-23 01:00AM	Addex Announces ADX71149 Phase 2 Epilepsy Clinical Studys Independent Interim Review Committee Recommends Continuing Study (GlobeNewswire) +26.27%
May-05-23 01:00AM	Addex Convenes Annual General Meeting 2023 (GlobeNewswire)
May-04-23 01:00AM	Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 (GlobeNewswire)
Apr-05-23 01:00AM	Addex Completes $5.0 Million Equity Financing (GlobeNewswire) -18.07%
Apr-04-23 01:00AM	Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinsons Disease (GlobeNewswire) -7.09%
Apr-03-23 01:00AM	Addex Raises $5.0 Million in Equity Financing (GlobeNewswire) +5.02%
Mar-30-23 01:00AM	Addex Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -14.16%
Mar-28-23 01:00AM	Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023 (GlobeNewswire)
Mar-16-23 02:00AM	Addex Announces Upcoming Conferences it will participate for H1 2023 (GlobeNewswire) +10.45%
Feb-09-23 01:00AM	Addex Regains Nasdaq Listing Compliance (GlobeNewswire) +9.97%
Feb-06-23 01:00AM	Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 (GlobeNewswire) -13.89%
Jan-19-23 01:00AM	Addex Provides Corporate Update and Financial Guidance (GlobeNewswire)
Dec-08-22 01:00AM	Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration (GlobeNewswire)
Nov-11-22 01:00AM	Addex Reports Q3 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 02:00AM	Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022 (GlobeNewswire)
02:00AM	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Nov-01-22 02:00AM	Addex Increases Issued Share Capital to Create Treasury Shares (GlobeNewswire) -5.88%
Sep-20-22 01:00AM	Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference (GlobeNewswire)
Aug-18-22 01:00AM	Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-15-22 01:00AM	Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders (GlobeNewswire)
Aug-12-22 01:00AM	Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022 (GlobeNewswire)
Jul-26-22 04:00PM	Addex Completes $4.2 Million Equity Financing (GlobeNewswire) -6.34%
Jul-22-22 01:00AM	Addex Raises $4.2 million in Equity Financing (GlobeNewswire)
Jul-21-22 01:00AM	Addex Provides Corporate Update and Financial Guidance (GlobeNewswire) +110.40%
01:00AM	Addex Completes Reduction in Nominal Value of Shares (GlobeNewswire)
Jun-17-22 01:00AM	Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinsons Disease due to Slow Recruitment Rate (GlobeNewswire) -55.16%
May-27-22 01:00AM	Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study (GlobeNewswire)
May-19-22 01:00AM	Addex Announces Participation in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 01:00AM	Addex Announces Participation in the 22nd Bioquity Europe Conference (GlobeNewswire)
May-10-22 01:00AM	Addex Shareholders Approve All Resolutions at Annual General Meeting (GlobeNewswire)
May-05-22 01:00AM	Addex Reports Q1 2022 Financial Results (GlobeNewswire) +7.93%
Apr-28-22 01:00AM	Addex to Present at the Swiss Biotech Day 2022 (GlobeNewswire) +7.28%
Apr-25-22 01:00AM	Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference (GlobeNewswire) -11.38%
Apr-13-22 01:00AM	Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study (GlobeNewswire)
Apr-06-22 01:00AM	Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders (GlobeNewswire)
Mar-31-22 01:00AM	Addex Convenes Annual General Meeting 2022 (GlobeNewswire) +9.72%
Mar-29-22 12:00PM	Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +12.06%
Mar-24-22 02:00AM	Addex to Present at the Bio-Europe Spring 2022 and Maxim Group 2022 Virtual Growth Conferences (GlobeNewswire)
Mar-10-22 01:10AM	Addex Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 01:00AM	Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022 (GlobeNewswire)
Feb-24-22 01:00AM	Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums (GlobeNewswire)
Feb-15-22 12:00PM	Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +11.44%
Feb-03-22 01:00AM	Addex Increases Issued Share Capital to Create Treasury Shares (GlobeNewswire)
Jan-11-22 01:00AM	Addex to Present at the Swiss Equities Baader Virtual Conference (GlobeNewswire)
Jan-06-22 01:00AM	Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-17-21 01:00AM	Addex Raises $10.0 Million in Equity Financing (GlobeNewswire)
Dec-15-21 01:00AM	Addex Provides Year End Pipeline Development Update (GlobeNewswire)
Nov-18-21 01:00AM	Addex to Present at the Virtual German Equity Forum (GlobeNewswire)
Nov-15-21 01:00AM	Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference (GlobeNewswire)
01:00AM	Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149 (GlobeNewswire)
Nov-04-21 02:00AM	Addex Reports Q3 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-21 02:00AM	Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021 (GlobeNewswire)
Oct-26-21 03:02PM	Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-06-21 01:00AM	Addex to Present at the Investors Day hosted by Voxia Communication (GlobeNewswire)
Oct-04-21 01:00AM	Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors (GlobeNewswire)
Sep-29-21 01:00AM	Addex to Present at the Cantor Global Healthcare 2021 Conference (GlobeNewswire)
01:00AM	Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm (GlobeNewswire)
Sep-22-21 01:00AM	CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A (GlobeNewswire)
Sep-08-21 01:00AM	Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-02-21 01:00AM	Addex to Present at the Swiss Biotech Day (GlobeNewswire)
Aug-05-21 01:00AM	Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-21 01:00AM	Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021 (GlobeNewswire) -7.82%
01:00AM	Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science (GlobeNewswire)
Jul-29-21 01:00AM	Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding (GlobeNewswire)
Jul-16-21 06:06AM	Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy? (Zacks) -5.80%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jul-07-21 01:00AM	Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021 (GlobeNewswire)

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADXN

Addex Therapeutics Ltd ADR

Upgrade your FINVIZ experience